B. Braun Closed Interventional Systems Division
The company is shutting down its medical device unit in Bethlehem, affecting 40 employees nationwide.
Updated on Oct. 9, 2026 in Healthcare
Live Poll
Do you feel the local job market is getting worse due to recent corporate layoffs?
B. Braun has announced the closure of its Interventional Systems division, which is based at the company's headquarters in Bethlehem. The decision impacts 40 employees across the United States as the firm shifts resources toward its core businesses.
Why it matters
This closure represents a strategic realignment for B. Braun as the company looks to focus its resources on its primary operational priorities. The transition aims to wind down the production and distribution of specialized medical devices while managing existing commitments.
The closure of the Interventional Systems division affects 40 employees, a move that follows the loss of 173 jobs during June 2026 site closures in Upper Macungie Township. Commercial sales for the affected unit are expected to continue into early 2027.
The players
B. Braun
A global medical technology company that focuses on therapy areas including infusion therapy and regional anesthesia.
QuVa Pharma Inc.
A company specializing in outsourcing services for compounded sterile preparations used in hospital settings.
Central Admixture Pharmacy Services Inc.
A provider of customized compounded medication services often utilized by large-scale healthcare providers.
The details
The division develops and manufactures medical devices specifically for pulmonology, cardiology, vascular surgery, and interventional radiology. B. Braun will manage the shutdown through a phased transition, coordinating with suppliers to ensure an orderly shift to new distributors.
Timeline
June 2026: Two B. Braun sites in Upper Macungie Township closed.
September 2026: QuVa Pharma acquired medications from CAPS.
October 9, 2026: B. Braun announced the division closure.
Early 2027: Commercial sales are expected to conclude.
March 2027: All division deliveries will officially end.
Market Landscape
This decision follows the company's ongoing consolidation of its Pennsylvania manufacturing footprint. The shift reflects a broader trend of large medical technology firms optimizing their operational portfolios to shed specialized units that fall outside of core strategic growth areas.
Customers who currently rely on the Interventional Systems division for specialized medical devices will need to transition to new distributors as B. Braun coordinates an orderly exit from the market. The company anticipates that product availability will remain steady through the first quarter of 2027.
The takeaway
The move underscores the importance of operational agility for large medical device manufacturers navigating competitive landscapes. Patients and providers should monitor the transition timeline to avoid potential service disruptions for specialized radiology and surgical products.
Further reading
Learn more about local industry trends in the Healthcare section.
Live Poll
Do you feel the local job market is getting worse due to recent corporate layoffs?
